Scribe Therapeutics to Participate in Upcoming Investor Conferences
Scribe Therapeutics (Nasdaq:SCTX) will participate in three investor events in September–October 2026.
Rhea-AI Summary
Scribe Therapeutics (Nasdaq:SCTX) will participate in three investor events in September–October 2026. Management joins the Wells Fargo Healthcare Conference in Boston on Sept. 9 at 8:00 AM ET, the H.C. Wainwright 28th Annual Global Investment Conference in New York on Sept. 15, and the Cell & Gene Meeting on the Mesa in Phoenix on Oct. 5 at 5:15 PM MT.
Positive
- None.
Negative
- None.
News Market Reaction – SCTX
In the Sep 1 session, SCTX declined 5.04%, reflecting a notable negative market reaction. Argus tracked a trough of -2.7% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ALAMEDA, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced that management will participate in the following upcoming investor conferences:
Wells Fargo Healthcare Conference
Boston, MA
Sept. 9, 2026 at 8:00 AM ET
Benjamin Oakes, Ph.D., Co-founder and CEO, will participate in a fireside chat.
H.C. Wainwright 28th Annual Global Investment Conference
New York, NY
Sept. 15, 2026
Benjamin Oakes, Ph.D., Co-founder and CEO, will present.
Cell & Gene Meeting on the Mesa
Phoenix, AZ
Oct. 5, 2026 at 5:15 PM MT
David Parrot, M.B.A., CFO, will deliver an Innovation Spotlight presentation.
About Scribe Therapeutics Inc.
Scribe Therapeutics is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Leveraging its CRISPR by Design™ approach and nature’s blueprint for improved cardiovascular health, Scribe’s initial programs focus on addressing the key drivers of ASCVD such as elevated LDL-C, lipoprotein(a), and triglycerides. The company’s lead candidate, STX-1150, is a novel liver-targeted therapy designed to epigenetically silence the PCSK9 gene and reduce LDL-C levels without inducing permanent DNA changes. To broaden and accelerate the impact of its engineered CRISPR technologies for patients, Scribe has formed strategic collaborations with world-leading pharmaceutical companies including Sanofi and Eli Lilly. Co-founded by Nobel Prize winner Jennifer Doudna and backed by leading life sciences investors, Scribe is advancing scalable, transformative, and preventative genetic medicines with the goal of improving outcomes and democratizing access to the protective effects of beneficial human genetics. To learn more, visit www.scribetx.com.
Investor Contact:
Investor Relations, Scribe Therapeutics
ir@scribetx.com
Media Contact:
Thermal for Scribe Therapeutics
media@scribetx.com
